INTRODUCTION AND OBJECTIVES: Hypogonadism may affect up to 70% of men with end stage renal disease (ESRD). This disorder has significant impact on sexual function, lean body mass, BMI, bone mineralization, hemoglobin levels and cardiovascular disease associated mortality. Our objective was to evaluate the incidence of hypogonadism in men with ESRD on a KTWL as well as its impact on QOL and sexual function.
METHODS: Patients with ESRD (40-70 years old), with at least 6 months on hemodialysis were selected (n[89). The studied parameters were age, total (TT) and free testosterone, FSH, LH, prolactin, SHBG, hemoglobin, albumin and BMI. Comparison between hypogonadic (GI, TT<300ng/ml on 2 separate measurements) and non-hypogonadic (GII) men was carried out. The WHO QOL and IIEF questionnaires were fulfilled.
RESULTS: Hypogonadism was observed in 24 (26.9%) men. Population data are showed in CONCLUSIONS: The incidence of hypogonadism in the studied population differs significantly from the literature suggesting the need for specific approaches. Patients with hypogonadism showed higher levels of BMI. IIEF and QOL were not different between groups
